Csl Ltd has released a press release.
CSL Half Year Results Investor Presentation
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from CSL
- CSL Statutory Accounts for the Half Year Ended 31 December
- CSL Half Year Results Announcement
- Paul McKenzie retires, Gordon Naylor appointed interim CEO
- Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years
- CSL to invest approximately $1.5b in U.S. to manufacture plasma-derived therapies
Later from CSL
- Neffy, adrenaline nasal spray, now approved to treat anaphylaxis in Australia
- Canada and CSL Seqirus, a Global Leader in Influenza Vaccines, agree on new Pandemic Preparedness Contract
- CSL announces expansion of Illinois plasma therapy manufacturing facility
- CSL: Seqirus Signs Long-Term Agreement with The Pan American Health Organization (PAHO) to Advance Regional Influenza Protection in the Region of the Americas
- CSL Seqirus Signs Long-Term Agreement with The Pan American Health Organization to Advance Regional Influenza Protection in the Region of the Americas
Follow CSL into a list and get an email when it puts out news.
Follow CSL